Cycle frequency: Every four weeks Total number of cycles: 6-8

Size: px
Start display at page:

Download "Cycle frequency: Every four weeks Total number of cycles: 6-8"

Transcription

1 Fludarabine Low Grade non-hodgkin s Lymphoma and CLL Fludarabine 25mg/m 2 oral Days 1-5 Cycle frequency: Every four weeks Total number of cycles: 6-8 Anti-emetic group Low Prophylactic co-trimoxazole and valaciclovir Round Fludarabine to the nearest 10mg Toxicities: Myelosuppression and risk of neutropenic sepsis or haemorrhage, nausea, mucositis, amenorrhoea, pneumonitis, carcinogenesis, infertility, hair thinning, fluid retention Symptomatic treatment of side effects: Mouth care Pre-treatment U &E s, LFTs, creatinine, urate CXR CXR After every two cycles Review in the Medical Oncology Clinic 4 weeks after last cycle Reference: Foran et al, J. Clin. Oncol., 17; pages rd Edition 88

2 Indication: CVP Low Grade non-hodgkin s lymphoma and CLL Cyclophosphamide 750mg/m 2 iv Day 1 Vincristine 1.4mg/m 2 (max 2mg) iv Day 1 Prednisolone 100mg oral Days 1-5 Cycle frequency: Every three weeks Total number of cycles: 6 Anti-emetic group Low Do not cap BSA vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, constipation, haemorrhagic cystitis, nephrotoxicity, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance After every two cycles Reference: Rosenberg SA, J. Clin. Oncol., 3; pages rd Edition 89

3 Indication: CVP-R Low Grade non-hodgkin s lymphoma and CLL Cyclophosphamide 750mg/m 2 iv Day 1 Vincristine 1.4mg/m 2 (max 2mg) iv Day 1 Prednisolone 100mg oral Days 1-5 Rituximab 375mg/m 2 500mls N. Saline Day 1 as per datasheet Cycle frequency: Every three weeks Total number of cycles: 6-8 Anti-emetic group Low Do not cap BSA Pre-med Rituximab paracetamol, chlorpheniramine, dexamethasone Rituximab Rapid Infusion guidelines apply vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, constipation, haemorrhagic cystitis, nephrotoxicity, diarrhoea, carcinogenesis, infertility, sensitivity reaction to rituximab, urate, creatinine clearance After every two cycles Reference: Marcus et al, Blood, 105; pages rd Edition 90

4 FMD Low Grade non-hodgkin s Lymphoma Fludarabine 25mg/m 2 iv/30mins Days 1-3 Mitozantrone 10mg/m 2 100ml N. Saline/10mins Day 1 Dexamethasone 20mg oral Days 1-5 Cycle frequency: Every four weeks Total number of cycles: 6 Anti-emetic group High on Day 1 Delay if neutrophils - < 1.0 x 10 9 /L or platelets < 100 x 10 9 /L Ensure adequate renal function Prophylactic co-trimoxazole and valaciclovir vomiting, mucositis, alopecia, cardiotoxicity, amenorrhoea, peripheral neuropathy, constipation, encephalopathy, haemorrhagic cystitis, nephrotoxicity, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance After three cycles Reference: Crawley et al, Ann. Oncol., 11; pages rd Edition 91

5 CHOP Non-Hodgkin s Lymphoma Drug Dose in/infusion/oral q Cyclophosphamide 750mg/m 2 iv Day 1 Doxorubicin 50mg/m 2 iv Day 1 Vincristine 1.4mg/m 2 (max 2mg) iv Day 1 Prednisolone 100mg oral Days 2-5 Cycle frequency: Every two to three weeks Total number of cycles: 6-8 Anti-emetic group Moderately high Delay if neutrophils <1.0 x 10 9 /L or platelets < 100 x 10 9 /L Ensure adequate renal function and liver function Do not cap BSA vomiting, mucositis, alopecia, cardiotoxicity, amenorrhoea, peripheral neuropathy, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance After every two cycles Reference: Coiffier et al, J. Clin. Oncol., 9; pages rd Edition 92

6 CHOP-R Non-Hodgkin s Lymphoma (B-cell) Cyclophosphamide 750mg/m 2 iv Day 1 Doxorubicin 50mg/m 2 iv Day 1 Vincristine 1.4mg/m 2 (max 2mg) iv Day 1 Prednisolone 100mg oral Days 2-5 Rituximab 375mg/m 2 500mls N. Saline Day 1 as per datasheet Cycle frequency: Every two to three weeks Total number of cycles: 6-8 Anti-emetic group Moderately High Delay if neutrophils <1.0 x 10 9 /L or platelets < 100 x 10 9 /L Ensure adequate renal function and liver function Rituximab should be given pre-chop on cycle 1, subsequent cycles the order does not matter Pre-med Rituximab paracetamol, chlorpheniramine, dexamethasone Rituximab Rapid Infusion guidelines apply Do not cap BSA vomiting, mucositis, alopecia, cardiotoxicity, amenorrhoea, peripheral neuropathy, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility, sensitivity reaction to rituximab Symptomatic treatment of side effects: Mouth care encourage oral fluids, urate, creatinine clearance After every two cycles Reference: Coiffier et al, N. Engl. J. Med., 346; pages rd Edition 93

7 CHOP-R (with Intrathecal Methotrexate) Non-Hodgkin s Lymphoma Cyclophosphamide 750mg/m 2 iv Day 1 Doxorubicin 50mg/m 2 iv Day 1 Vincristine 1.4mg/m 2 (max 2mg) iv Day 1 Prednisolone 100mg oral Days 2-5 Rituximab 375mg/m 2 500mls N. Saline Day 1 Methotrexate 12.5mg I/T Day 1 Cycle frequency: Every two to three weeks Total number of cycles: 6-8 Anti-emetic group Moderately High Delay if neutrophils <1.0 x 10 9 /L or platelets < 100 x 10 9 /L Ensure adequate renal function and liver function Intrathecal methotrexate to be given in accordance with local policy Rituximab should be given pre-chop on cycle 1, subsequent cycles the order does not matter Pre-med Rituximab paracetamol, chlorpheniramine, dexamethasone Rituximab Rapid Infusion guidelines apply Do not cap BSA vomiting, mucositis, alopecia, cardiotoxicity, amenorrhoea, peripheral neuropathy, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility, sensitivity reaction to rituximab, post-lumbar puncture headache, meningeal irritation Symptomatic treatment of side effects: Mouth care encourage oral fluids, urate, creatinine clearance Reference: Coiffier et al, N. Engl. J. Med., 346; pages rd Edition 94

8 PIE (Cisplatin/Ifosfamide/Etoposide) Lymphoma - Recurrent Etoposide 133mg/m 2 500mls N. Saline/2hr Days 1-3 Ifosfamide 2,000mg/m 2 1L N. Saline/4 hrs Days 1-3 Cisplatin 33mg/m 2 1L N. Saline/2hrs Days 1-3 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group High Ensure adequate renal function Pre & post hydration, mannitol, potassium & magnesium Mesna dose guidelines vomiting, mucositis, alopecia, cardiotoxicity, peripheral neuropathy, nephrotoxicity, ototoxicity, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility U & E s, LFTs, Mg 2+, Ca 2+, creatinine, urate, creatinine clearance U & E s, LFTs, Mg 2+, Ca 2+, creatinine After each cycle Reference: Gupta, rd Edition 95

9 R-ICE (Carboplatin/Ifosfamide/Etoposide) Lymphoma - Recurrent Rituximab 375mg/m 2 500mls N. Saline Day 1 Etoposide 100mg/m 2 500mls N. Saline/2hr Days 1-3 Ifosfamide 5,000mg/m 2 1L N. Saline/24 hrs Day 2 Carboplatin AUC 5 500mls 5% dextrose/1hrs Day 2 Cycle frequency: Every 2 weeks Total number of cycles: 3 Anti-emetic group High Ensure adequate renal function, hydration Mesna dose guidelines apply Prophylactic pegylated G-CSF on day 5 Pre-med Rituximab paracetamol, chlorpheniramine, dexamethasone Rituximab Rapid Infusion guidelines apply vomiting, mucositis, alopecia, cardiotoxicity, peripheral neuropathy, nephrotoxicity, ototoxicity, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility U & E s, LFTs, Mg 2+, Ca 2+, creatinine, urate, creatinine clearance U & E s, LFTs, Mg 2+, Ca 2+, creatinine After each cycle Reference: Kewalramani et al, Blood, 103; pages rd Edition 96

10 VAPEC-B Non-Hodgkin s Lymphoma Cyclophosphamide 350mg/m 2 iv Day 1 Doxorubicin 35mg/m 2 iv Days 1 & 15 Vincristine 1.4mg/m 2 iv (max 2mg) Days 8 & 22 Bleomycin 10,000iu/m 2 200mls N. Saline/30mins Day 8 Etoposide 100mg/m 2 oral Days Prednisolone 50mg/m 2 daily Weeks 1-6 Prednisolone 25mg/m 2 daily Weeks 7-12 Cycle frequency: Every four weeks Total number of cycles: 3 Dose modification: Discuss with Consultant Anti-emetic group Moderately high on days 1 and 15 Ensure adequate renal function and liver function Prophylactic PPI and co-trimoxazole Round Etoposide dose to the nearest 50mg vomiting, mucositis, alopecia, cardiotoxicity, amenorrhoea, peripheral neuropathy, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance After every cycle Review in the Medical Oncology Clinic 4 weeks after last cycle Reference: Radford et al, Ann. Oncol., 5; pages rd Edition 97

11 Indication: Rituximab (Mabthera) Non Hodgkin s Lymphoma Rituximab 375mg/m 2 500mls N. Saline Day 1 as per datasheet Cycle frequency: Every week Total number of cycles: 4 (8) Dose modification: Discuss with Consultant Anti-emetic group Low Pre-med Rituximab paracetamol, chlorpheniramine, dexamethasone Rituximab Rapid Infusion guidelines apply Toxicities: Myelosuppression and risk of neutropenic sepsis or haemorrhage, nausea, hyper-sensitivity reaction, carcinogenesis, infertility, allergic-like reaction, bronchospasm, hypotension, cardiotoxicity, chills/fevers, rigors Symptomatic treatment of side effects: Supportive therapy, urate Reference: Davis et al, J. Clin. Oncol., 17; pages rd Edition 98

12 ESHAP Recurrent lymphoma and Hodgkin s disease Cisplatin 25mg/m 2 iv continuous infusion Days 1-4 Etoposide 40mg/m 2 500mls N. Saline/1hr Days 1-4 Methylprednisolone 500mg 100ml N. Saline/30mins Days 1-5 Cytarabine 2000mg/m 2 500mls N. Saline/2hrs Day 5 Cycle frequency: Every three-four weeks Total number of cycles: 6 Anti-emetic group High Delay if neutrophils < 1.5 x 10 9 /L or platelets < 100 x 10 9 /L Ensure adequate renal function Pre & post hydration, mannitol, potassium & magnesium Double/triple lumen Hickman line required Pre-mild eye drops post cytarabine vomiting, mucositis, conjunctivitis, alopecia, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, red skin, carcinogenesis, infertility, ESR U & E s, LFTs, Mg 2+, Ca 2+, creatinine, urate, creatinine clearance inc. CT scans, ESR U & E s, LFTs, Mg 2+, Ca 2+, creatinine CXR Re-assess prior to third cycle Reference: Velasquez et al, J. Clin. Oncol., 12; pages rd Edition 99

Cycle frequency: Every three weeks Total number of cycles: 6

Cycle frequency: Every three weeks Total number of cycles: 6 Carboplatin/Paclitaxel Ovarian Cancer Adjuvant, Advanced Paclitaxel 175mg/m 2 500mls 5% dex/3hrs Day 1 Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Anti-emetic group - Moderately high Paclitaxel given first

More information

Schedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2

Schedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2 Doxorubicin/Cisplatin Osteosarcoma - neoadjuvant Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2 (3 before surgery) Ensure adequate renal function Pre & post-hydration,

More information

Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8

Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total

More information

Cycle frequency: Every three weeks Total number of cycles: 3 or 4

Cycle frequency: Every three weeks Total number of cycles: 3 or 4 BEP 3-day (Bleomycin/Etoposide/Cisplatin) Germ cell tumours Bleomycin 30,000iu 200mls N. Saline/30mins Days 2, 8 & 15 Etoposide 165mg/m 2 1L N. Saline/1hr Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/4hrs

More information

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) West of Scotland Cancer Network Chemotherapy Protocol Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) Indication Palliative chemotherapy for malignant mesothelioma of the pleura Eligibility

More information

NORDIC. Indication Mantle cell lymphoma (for patients suitable for subsequent chemotherapy with haematopoietic stem cell rescue)

NORDIC. Indication Mantle cell lymphoma (for patients suitable for subsequent chemotherapy with haematopoietic stem cell rescue) NORDIC C) CODOX (R) CODOX M/ (R) IVAC Indication Mantle cell lymphoma (for patients suitable for subsequent chemotherapy with haematopoietic stem cell rescue) ICD-10 code C83.13 Regimen details (R) maxi-chop

More information

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed

More information

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Background: A non-anthracycline based regimen for high-risk, HER 2 positive breast cancer in the adjuvant setting (BCIRG 006). Patient

More information

Fludarabine based chemotherapy [Fludarabine, FC, FCR, FMD]

Fludarabine based chemotherapy [Fludarabine, FC, FCR, FMD] Approved Haematology Chemotherapy Protocol Fludarabine based chemotherapy [Fludarabine, FC, FCR, FMD] MCCN Ref OPCS Proc OPCS Del CLFLUD X70.5 X72.3 IV CLFC X70.4 X72.2 IV X73.1 O CLFCR X71.5 X72.1 LYFMD

More information

Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral)

Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral) Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral) Indication CLL 1st line as per NICE TAG 174 CLL (relapsed) as per NICE TAG 193 Regimen details Day Drug Dose Route Cycle 1 1 Rituximab 375mg/m

More information

Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.

Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate. EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human

More information

In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:

In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes: EMA/614203/2010 EMEA/H/C/000165 EPAR summary for the public rituximab This is a summary of the European public assessment report (EPAR) for. It explains how the Committee for Medicinal Products for Human

More information

BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)

BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP) BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP) Protocol Code Tumour Group Contact Physician UGUTIP Genitourinary Dr.

More information

Network Chemotherapy Regimens

Network Chemotherapy Regimens Network Chemotherapy Regimens Lung Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.org.uk. Any correspondence about the protocols

More information

West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol

West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol FEC-DH in the adjuvant treatment of Breast Cancer (BRWOS- 031/1) Indication Adjuvant chemotherapy for HER2+ve Early Breast Cancer Eligibility

More information

Thames Valley Chemotherapy Regimens

Thames Valley Chemotherapy Regimens Chemotherapy Regimens Lung Cancer Notes from the editor These regimens are available on the Network website www.tvcn.org.uk. Any correspondence about the regimens should be addressed to: Sally Coutts,

More information

Breast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer

Breast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer Breast Pathway Group AC (Doxorubicin / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment of breast cancer Regimen details: Doxorubicin 60mg/m 2 IV Day 1 Cyclophosphamide

More information

PREMEDICATIONS: Agent(s) Dose Route Schedule

PREMEDICATIONS: Agent(s) Dose Route Schedule BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group

More information

Docetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer

Docetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer Regimen: Docetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer Indication Approved for the treatment of early and locally advanced breast cancer in

More information

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Indication: Neoadjuvant or adjuvant therapy for elderly and frail patients with breast

More information

Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Early Breast Cancer

Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Early Breast Cancer Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Indication: Neoadjuvant or adjuvant therapy in node positive patients. Also considered in

More information

Regimen: Gemcitabine & Carboplatin for NSCLC

Regimen: Gemcitabine & Carboplatin for NSCLC Regimen: Gemcitabine & Carboplatin for NSCLC ICD10 codes Codes pre-fixed with C34. Indications Regimen details First-line chemotherapy for advanced (stage IIIB/IV) non-small cell lung cancer (NICE CG121)

More information

London Cancer. Mesothelioma Lung Protocols

London Cancer. Mesothelioma Lung Protocols London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta

More information

Thames Valley Cancer Network. Network Chemotherapy Protocols Breast Cancer

Thames Valley Cancer Network. Network Chemotherapy Protocols Breast Cancer Network Chemotherapy Protocols Breast Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.nhs.uk. Any correspondence about the protocols

More information

Regimen: Fluorouracil, Epirubicin and Cyclophosphamide + Docetaxel (FEC/T) for Early Breast Cancer

Regimen: Fluorouracil, Epirubicin and Cyclophosphamide + Docetaxel (FEC/T) for Early Breast Cancer Regimen: Fluorouracil, Epirubicin and Cyclophosphamide + Docetaxel (FEC/T) for Early Breast Cancer Indication Adjuvant treatment for node positive early breast cancer This protocol is subject to local

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007

More information

This 2-part article will discuss 9 anticancer. Commonly Used Chemotherapy Drugs Part 1. M e d i c a t i o n s. Clinician s Brief.

This 2-part article will discuss 9 anticancer. Commonly Used Chemotherapy Drugs Part 1. M e d i c a t i o n s. Clinician s Brief. M e d i c a t i o n s O N C O L O G Y Peer Reviewed Antony Moore, BVSc, MVSc, Diplomate ACVIM (Oncology) Veterinary Oncology Consultants, Sydney, Australia Commonly Used Chemotherapy Drugs Part 1 This

More information

rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited

rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited 06 June 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line

More information

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

AC-Docetaxel: Doxorubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer

AC-Docetaxel: Doxorubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer AC-Docetaxel: Doxubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer Indication: Neoadjuvant therapy f high risk and fit Breast Cancer patients, suitable f a taxane containing regimen AC Regimen

More information

BCCA Protocol Summary for Central Nervous System Prophylaxis with High Dose Methotrexate, CHOP and rituximab in Diffuse Large B-cell Lymphoma

BCCA Protocol Summary for Central Nervous System Prophylaxis with High Dose Methotrexate, CHOP and rituximab in Diffuse Large B-cell Lymphoma BCCA Protocol Summary for Central Nervous System Prophylaxis with High Dose Methotrexate, CHOP and rituximab in Diffuse Large B-cell Lymphoma Protocol Code Tumour Group Contact Physician LYCHOPRMTX Lymphoma

More information

Case Report in Oncology Pharmacy. Therapy and supportive care of a high-grade non-hodgkin s lymphoma

Case Report in Oncology Pharmacy. Therapy and supportive care of a high-grade non-hodgkin s lymphoma Patient: 75 years old, female, 157 cm, 68 kg, BSA 1.69 m² Subjective data Objective data At the time of diagnosis L.K. was a 75 year old woman who, in December 2007, was referred by her family doctor to

More information

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress Rescue Chemotherapy Protocols for Dogs with Lymphoma Kenneth M. Rassnick, DVM, DACVIM (Oncology) Cornell University

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

1 PRACTICAL ISSUES IN CYTOTOXIC

1 PRACTICAL ISSUES IN CYTOTOXIC 1 PRACTICAL ISSUES IN CYTOTOXIC CHEMOTHERAPY USAGE Introduction Inthischapter, theprinciplesofcytotoxicchemotherapy treatment and the appropriate use of anticancer drugs, including some of the new targeted

More information

Cyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft

Cyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft INDICATIONS Cyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft Aplastic Anaemia (patients under 40 years) PRE-ASSESSMENT Ensure pre-transplant work-up form is complete Ensure patient has triple

More information

CHEMOTHERAPY PROTOCOLS V10.1

CHEMOTHERAPY PROTOCOLS V10.1 CHEMOTHERAPY PROTOCOLS V10.1 Issue Date: 10 th July 2014 Page 1 of 42 Filename: MCHACPROTO Issue No: 10.1 CCC Chemotherapy Protocols Haematological Malignancies... 3 Hodgkins disease...3 Non-Hodgkins Lymphoma...5

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Salvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma

Salvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma IMAJ VOL 11 January 9 Salvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma Ariela Dortort Lazar MD 1,, Ofer Shpilberg

More information

Hydration Protocol for Cisplatin Chemotherapy

Hydration Protocol for Cisplatin Chemotherapy Betsi Cadwaladr University Health Version: 1.3 CSPM2 Hydration Protocol for Cisplatin Chemotherapy Date to be reviewed: July 2018 No of pages: 9 Author(s): Tracy Parry-Jones Author(s) title: Lead Cancer

More information

5-Fluorouracil & Radiotherapy for Adjuvant Oesophageal or Gastric Cancer (Modified Macdonald Protocol)

5-Fluorouracil & Radiotherapy for Adjuvant Oesophageal or Gastric Cancer (Modified Macdonald Protocol) 5-Fluorouracil & Radiotherapy for Adjuvant Oesophageal or Gastric Cancer (Modified Macdonald Protocol) Indication: Adjuvant Chemo-radiotherapy for patients with resectable adenocarcinoma of the stomach

More information

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) Protocol Code Tumour Group Contact Physician UBRAVKAD Breast Dr Stephen Chia ELIGIBILITY:

More information

David Loew, LCL MabThera

David Loew, LCL MabThera MabThera The star continues to rise David Loew, LCL MabThera MabThera the star continues to raise Group sales (CHF bn) 4,5 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 2001 2002 2003 2004 2005 Outstanding clinical

More information

Regimen: Pegylated Liposomal Doxorubicin Hydrochloride (PLDH) (Caelyx ) and Carboplatin ( CALYPSO regimen)

Regimen: Pegylated Liposomal Doxorubicin Hydrochloride (PLDH) (Caelyx ) and Carboplatin ( CALYPSO regimen) Regimen: Pegylated Liposomal Doxorubicin Hydrochloride (PLDH) (Caelyx ) and Carboplatin ( CALYPSO regimen) Indications This is NOT a NICE-approved treatment. Please ensure that this regimen is locally

More information

DE Tsai 1, HCF Moore 1, CL Hardy 2, DL Porter 1, EY Loh 1, DJ Vaughn 1, S Luger 1, SJ Schuster 1 and EA Stadtmauer 1

DE Tsai 1, HCF Moore 1, CL Hardy 2, DL Porter 1, EY Loh 1, DJ Vaughn 1, S Luger 1, SJ Schuster 1 and EA Stadtmauer 1 Bone Marrow Transplantation, (1999) 24, 521 526 1999 Stockton Press All rights reserved 0268 3369/99 $15.00 http://www.stockton-press.co.uk/bmt Rituximab (anti-cd20 monoclonal antibody) therapy for progressive

More information

Treatment of low-grade non-hodgkin lymphoma

Treatment of low-grade non-hodgkin lymphoma Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade

More information

Adverse Effects of Chemotherapy

Adverse Effects of Chemotherapy Problems with Chemotherapy of Lymphoma--How to Cope Laura Blackwood, BVMS (Hons), MVM, PhD, CertVR, DECVIM-CA (Oncology), MRCVS Small Animal Teaching Hospital, University of Liverpool, Leahurst Campus

More information

Regimen : EOX (Epirubicin, Oxaliplatin and Capecitabine (Xeloda ))

Regimen : EOX (Epirubicin, Oxaliplatin and Capecitabine (Xeloda )) Regimen : EOX (Epirubicin, Oxaliplatin and Capecitabine (Xeloda )) Indication Regimen details Administration First line palliative treatment for locally advanced, inoperable oesophago-gastric cancer for

More information

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma

More information

Lymphoma: The Roleof Nurses in the Treatment Process

Lymphoma: The Roleof Nurses in the Treatment Process Lymphoma: The Roleof Nurses in the Treatment Process Sarah Liptrott MSc,BN(Hons), RN Istituto Europeo di Oncologia, Milan (IT) EBMT Swiss Study Day 2014, Zurich, Switzerland LymphomaManagement Watch &

More information

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy

More information

CHOP Chemotherapy Regimen for Lymphoma Information for Patients

CHOP Chemotherapy Regimen for Lymphoma Information for Patients CHOP Chemotherapy Regimen for Lymphoma Information for Patients The Regimen Contains: C: Cytoxan (cyclophosphamide) H: Adriamycin (hydroxy doxorubicin) O: vincristine (Oncovin ) P: Prednisone How Is This

More information

DIFFUSE LARGE B-CELL LYMPHOMA

DIFFUSE LARGE B-CELL LYMPHOMA DIFFUSE LARGE B-CELL LYMPHOMA Executive Summary Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-hodgkin lymphoma (NHL), constituting up to 40% of all cases globally.[1] This subtype

More information

Cytotoxic and Biotherapies Credentialing Programme Module 5

Cytotoxic and Biotherapies Credentialing Programme Module 5 Cytotoxic and Biotherapies Credentialing Programme Module 5 1. Drug Dose Determination 2. Drug Calculations 3. Role of the Second Checker 4. The Checking Process At the completion of this module the RN

More information

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine Capecitabine Capecitabine 1000-1250mg/m 2 oral TWICE daily for 14 days Until disease progression Capecitabine + Docetaxel Capecitabine 750-1000mg/m 2 oral TWICE daily for 14 days Up to 6 cycles Capecitabine

More information

Breast Cancer. Breast Cancer Page 1

Breast Cancer. Breast Cancer Page 1 Breast Cancer Summary Breast cancers which are detected early are curable by local treatments. The initial surgery will give the most information about the cancer; such as size or whether the glands (or

More information

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage

More information

WM: Managing the Side Effects of Treatment

WM: Managing the Side Effects of Treatment WM: Managing the Side Effects of Treatment 2014 IWMF Educational Forum Jeffrey V. Matous, MD Colorado Blood Cancer Institute www.bloodcancerinstitute.com Tampa, FL May 17, 2014 Determining a side effect

More information

Cryptococcal Screening Program Case Studies

Cryptococcal Screening Program Case Studies Slide 1 Cryptococcal Screening Program Case Studies Image courtesy of World Health Organization National Center for Emerging and Zoonotic Infectious Diseases Mycotic Diseases Branch Slide 2 Note to trainers

More information

Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital

Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens

More information

CVP Chemotherapy Regimen for Lymphoma Information for Patients

CVP Chemotherapy Regimen for Lymphoma Information for Patients CVP Chemotherapy Regimen for Lymphoma Information for Patients The Regimen Contains: C: Cyclophosphamide (Cytoxan ) V: Vincristine (Oncovin ) P: Prednisone How Is This Regimen Given? CVP is given every

More information

3 Regime Prescription Practical considerations 4 Pre-infusion Assessment 4 Administration. 5 Checklist. 5 Administering the infusion

3 Regime Prescription Practical considerations 4 Pre-infusion Assessment 4 Administration. 5 Checklist. 5 Administering the infusion Guidelines for the use and administration of Rituximab in Rheumatoid Arthritis (RA) (To be used in conjunction with local policies for intravenous infusions) Contents Page Introduction 1 Licensed Indication

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable

More information

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Aggressive lymphomas. Michael Crump Princess Margaret Hospital Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:

More information

Managing Lymphoma. Professor Clare Knottenbelt BVSc MSc DSAM MRCVS

Managing Lymphoma. Professor Clare Knottenbelt BVSc MSc DSAM MRCVS Managing Lymphoma Professor Clare Knottenbelt BVSc MSc DSAM MRCVS Lymphoma Common cancer (18% of dog cancers) DOGS: Multicentric CATS: Alimentary Presentation varies with site of LSA and paraneoplastic

More information

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,

More information

IV Thiotepa/Busulfan/Fludarabine/ATG for Allograft

IV Thiotepa/Busulfan/Fludarabine/ATG for Allograft Oxford BT Programme IV Thiotepa/Busulfan/Fludarabine/ATG for Allograft INDICATIONS Acute myeloid leukaemia, acute lymphoblastic leukaemia, non-hodgkin s lymphoma: for related and unrelated donor allogeneic

More information

1 Acute Myeloid Leukaemia

1 Acute Myeloid Leukaemia 1 Acute Myeloid Leukaemia 1.17 Idarubicin Pre-treatment Evaluation Morphology of blood and bone marrow aspirate. Trial patients: send 6 unstained slides to Leeds General Infirmary. Trephine biopsy and

More information

Treatment of Small Cell Lung Cancer

Treatment of Small Cell Lung Cancer Chapter 5 Treatment of Small Cell Lung Cancer Ariel Lopez-Chavez MD, MS Introduction There are two main types of lung cancer, non-small cell lung cancer and small cell lung cancer. 1 It is important that

More information

Basics of Systemic Anticancer Therapy Prescribing and Verification

Basics of Systemic Anticancer Therapy Prescribing and Verification CHAPTER 2 Basics of Systemic Anticancer Therapy Prescribing and Verification Trinh Pham Joan Rivington Learning Objectives Upon completion of the chapter, the reader will be able to: 1. Write clear and

More information

Shared Care Guideline for the use of Leflunomide for Rheumatoid Arthritis

Shared Care Guideline for the use of Leflunomide for Rheumatoid Arthritis Shared Care Guideline for the use of Leflunomide for Rheumatoid Section 1: Agreement for transfer of prescribing to GP Please sign this form and return it to the named consultant if you are willing to

More information

To report SUSPECTED ADVERSE REACTIONS, contact Millennium Pharmaceuticals at 1-866 VELCADE or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact Millennium Pharmaceuticals at 1-866 VELCADE or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VELCADE safely and effectively. See full prescribing information for VELCADE. VELCADE (bortezomib)

More information

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto Evolution of Lymphoma Therapy: What can we expect for the rest of the millenium decade? Michael Crump MD Lymphoma Site Leader Princess Margaret Hospital University of Toronto disclaimers Served on advisory

More information

Frequency of NHL Subtypes in Adults

Frequency of NHL Subtypes in Adults Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults

More information

Rituximab-Based Chemotherapy and

Rituximab-Based Chemotherapy and 用 藥 安 全 Drug Safety Rituximab-Based Chemotherapy and Late-Onset Neutropenia Yi-Ling Lu, Wan-Tsui Huang, Chi-Lan Kao, Hsi-Yen Lin Department of Pharmacy, Cathay General Hospital, Taipei, Taiwan Abstract

More information

autoimmune disease New biotherapy drugs and older chemotherapy agents may improve quality of life in patients with autoimmune diseases.

autoimmune disease New biotherapy drugs and older chemotherapy agents may improve quality of life in patients with autoimmune diseases. Chemotherapy and biotherapy drugs for autoimmune disease m New biotherapy drugs and older chemotherapy agents may improve quality of life in patients with autoimmune By Nancy E. Thompson, MS, RN, AOCNS

More information

J Clin Oncol 22:4302-4311. 2004 by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 22:4302-4311. 2004 by American Society of Clinical Oncology INTRODUCTION VOLUME 22 NUMBER 21 NOVEMBER 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin s Lymphoma: A Nationwide

More information

Good symptom relief with palliative MVP (mitomycin-c, vinblastine and cisplatin) chemotherapy in malignant mesothelioma

Good symptom relief with palliative MVP (mitomycin-c, vinblastine and cisplatin) chemotherapy in malignant mesothelioma Annals of Oncology 9: 9-7, 998. 998 Khmer Academic Publishers. Printed in the Netherlands Original article Good symptom relief with palliative MVP (mitomycin-c, vinblastine and cisplatin) chemotherapy

More information

Chemotherapy for lung cancer

Chemotherapy for lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 8. Contents Chemoradiation Small cell lung cancer

More information

(Form to be on hospital/institution headed paper) INCA TRIAL PATIENT INFORMATION SHEET

(Form to be on hospital/institution headed paper) INCA TRIAL PATIENT INFORMATION SHEET (Form to be on hospital/institution headed paper) INCA TRIAL PATIENT INFORMATION SHEET A multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin plus Rituximab and CVP (IO-R-CVP) versus

More information

Out-Patient Chemotherapy for Lung Cancer

Out-Patient Chemotherapy for Lung Cancer Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent

More information

Introduction of Rituximab in Front-Line and Salvage Therapies Has Improved Outcome of Advanced-Stage Follicular Lymphoma Patients

Introduction of Rituximab in Front-Line and Salvage Therapies Has Improved Outcome of Advanced-Stage Follicular Lymphoma Patients 2077 Introduction of Rituximab in Front-Line and Salvage Therapies Has Improved Outcome of Advanced-Stage Follicular Lymphoma Patients Stefano Sacchi, MD 1 Samantha Pozzi, MD 1 Luigi Marcheselli, MS 1

More information

For the Patient: CHOP-R Other names: LYCHOP-R

For the Patient: CHOP-R Other names: LYCHOP-R 1 For the Patient: CHOP-R Other names: LYCHOP-R C H O P R Cyclophosphamide Doxorubicin (also known as ADRIAMYCIN ) Vincristine (also known as ONCOVIN ) Prednisone (taken by mouth) Rituximab (also known

More information

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Update in Hematology Oncology Targeted Therapies. Mark Holguin Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning

More information

Vincristine by short infusion Doxorubicin by injection Cyclophosphamide by injection Rituximab by an infusion over between 60 minutes to a few hours

Vincristine by short infusion Doxorubicin by injection Cyclophosphamide by injection Rituximab by an infusion over between 60 minutes to a few hours R-CHOP R-CHOP This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others

More information

Cytotoxic and Biotherapies Credentialing Programme Module 2

Cytotoxic and Biotherapies Credentialing Programme Module 2 Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal

More information

Background Information Myeloma

Background Information Myeloma Myeloma FAST FACTS Myeloma, also known as multiple myeloma, is a type of cancer that develops from plasma cells which originate in the bone marrow 1 Myeloma is the second most common type of blood cancer

More information

Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment

Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment A Patient s Guide Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment Recommendations of the American Society of Clinical Oncology The American Society of Clinical Oncology (ASCO) is

More information

Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre

Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre Background Non-Hodgkin s lymphoma (NHL) makes up approximately 85% of all lymphomas. They are a heterogeneous collection

More information

Lung Cancer - Combination Chemotherapy and the Risk of Failure

Lung Cancer - Combination Chemotherapy and the Risk of Failure Evidence-based Series 7-13-1 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) The Role of Combination Chemotherapy in the Initial Management of Limited-Stage

More information

ONCOLOGY LETTERS 8: 2012-2016, 2014

ONCOLOGY LETTERS 8: 2012-2016, 2014 2012 Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-hodgkin's lymphoma patients with a poor performance status or comorbidity XUEDE

More information

Dr P Savage Date Review date: October 2015. Gemcitabine Regimens 1. Gemcitabine-1250/Cisplatin-70 D1+8 CTIS 1695 2

Dr P Savage Date Review date: October 2015. Gemcitabine Regimens 1. Gemcitabine-1250/Cisplatin-70 D1+8 CTIS 1695 2 BLADDER CANCER / TRANSITIONAL CELL CARCINOMA Section by: Dr Philip Savage, Professor Jonathan Waxman, Dr Alison Falconer, Dr Simon Stewart. Version: Bladder Cancer/TCC Regimens Approved v7.01 NWLCN 15Oct13

More information

New Treatment Options for Breast Cancer

New Treatment Options for Breast Cancer New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of

More information

This regimen has low emetogenic potential refer to local protocol None required routinely. Baseline results valid for 7 days. Results valid for 72 hrs

This regimen has low emetogenic potential refer to local protocol None required routinely. Baseline results valid for 7 days. Results valid for 72 hrs Regimen : Ipilimumab for Advanced Melanoma ICD10 code Codes pre-fixed with C43. Indication Regimen detail Ipilimumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma

More information